Riccardo Giannini - Concepedia

Author

Riccardo Giannini

Also Known As

GIANNINI R., Giannini R, Giannini Riccardo, Giannini, Riccardo, R GIANNINI, R Giannini, R. Giannini, R., Giannini, RICCARDO GIANNINI, Riccardo GIANNINI

151

Publications

6.4K

Citations

H-Index

108

Concepts

All Affiliations

University of Pisa Azienda Ospedaliera Universitaria Pisana Institute for Experimental Endocrinology and Oncology University of Insubria Istituto di Genetica Molecolare

About

Riccardo Giannini is an author at University of Pisa specializing in medicine, biology, and pathology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	25	1.3K
2	Natural Sciences	8	8	340
3	Health Sciences	5	5	354
4	Engineering	3	3	128
5	Management	1	1	48

Riccardo Giannini

Publications

5.8K

Citations

H-Index

Page 1

	Year	Citations
BRAF Mutations in Thyroid Tumors Are Restricted to Papillary Carcinomas and Anaplastic or Poorly Differentiated Carcinomas Arising from Papillary Carcinomas Marina N. Nikiforova, Edna Teruko Kimura, Manoj Gandhi, The Journal of Clinical Endocrinology & Metabolism	2003	1.1K
BRAFV600E Mutation and Outcome of Patients with Papillary Thyroid Carcinoma: A 15-Year Median Follow-Up Study Rossella Elisei, Clara Ugolini, David Viola, The Journal of Clinical Endocrinology & Metabolism	2008	525
Association of BRAF V600E Mutation with Poor Clinicopathological Outcomes in 500 Consecutive Cases of Papillary Thyroid Carcinoma Cristiana Lupi, Riccardo Giannini, Clara Ugolini, The Journal of Clinical Endocrinology & Metabolism	2007	393
Analysis of BRAF Point Mutation and RET/PTC Rearrangement Refines the Fine-Needle Aspiration Diagnosis of Papillary Thyroid Carcinoma Giuliana Salvatore, Riccardo Giannini, Pinuccia Faviana, The Journal of Clinical Endocrinology & Metabolism Ret/ptc Rearrangement RefinesBraf MutationPoint MutationsMedicineBraf Mutations	2004	265
The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells Rosa Marina Melillo, Maria Domenica Castellone, Valentina Guarino, Journal of Clinical Investigation	2005	237
The<i>BRAF</i>V600E Mutation Is an Independent, Poor Prognostic Factor for the Outcome of Patients with Low-Risk Intrathyroid Papillary Thyroid Carcinoma: Single-Institution Results from a Large Cohort Study Rossella Elisei, David Viola, Liborio Torregrossa, The Journal of Clinical Endocrinology & Metabolism	2012	235
Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants Xiaoguang Shi, Rengyun Liu, Fulvio Basolo, The Journal of Clinical Endocrinology & Metabolism	2015	201
Correlation between the <i>BRAF</i> V600E Mutation and Tumor Invasiveness in Papillary Thyroid Carcinomas Smaller than 20 Millimeters: Analysis of 1060 Cases Fulvio Basolo, Liborio Torregrossa, Riccardo Giannini, The Journal of Clinical Endocrinology & Metabolism	2010	184
Role of<i>NRAS</i>mutations as prognostic and predictive markers in metastatic colorectal cancer Marta Schirripa, Chiara Cremolini, Fotios Loupakis, International Journal of Cancer	2014	157
Potent Mitogenicity of the RET/PTC3 Oncogene Correlates with Its Prevalence in Tall-Cell Variant of Papillary Thyroid Carcinoma Fulvio Basolo, Riccardo Giannini, C Monaco, American Journal Of Pathology Oncogenic AgentMedicinePapillary Thyroid CarcinomaThyroid DiseasePathology	2002	114

Page 1